Roche调查新药Trontinemab 以延缓阿尔茨海默氏症,引入精确的血液测试Elecsys pTau217。 Roche investigates new drug Trontinemab to delay Alzheimer's, introduces precise blood test Elecsys pTau217.

瑞士的Roche制药公司计划调查其新药Trontinemab是否能延缓或预防有认知下降风险的个人老年痴呆症症状。 Swiss pharmaceutical company Roche plans to investigate if its new drug, Trontinemab, can delay or prevent Alzheimer's symptoms in individuals at risk of cognitive decline. 该药物旨在跨越血脑屏障,以更好地提供治疗。 The drug aims to cross the blood-brain barrier for better treatment delivery. Roche还引入了一种新的血液测试,Elecsys pTau217,用于检测阿尔茨海默氏病,这与脑扫描一样准确。 Roche also introduced a new blood test, Elecsys pTau217, for Alzheimer's detection, which is as accurate as brain scans. Eli Lilly和Eisai等与生物基因的竞争者也在实地取得进展,但他们的治疗费用昂贵,有造成严重副作用的危险。 Competitors like Eli Lilly and Eisai with Biogen are also progressing in the field, but their treatments are expensive and carry risks of serious side effects.